Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05241873 · ClinicalTrials.gov registry record · Phase 1
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
A Phase 1 study, sponsored by Blueprint Medicines Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
NCT05241873: Clinical Trial Phase 1 study, sponsored by Blueprint Medicines Corporation.
NCT05241873 is a Phase 1 study that was terminated before completion, run by Blueprint Medicines Corporation. The registered enrollment target is 103 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05241873, a Phase 1 study, was terminated before completion, sponsored by Blueprint Medicines Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
Study Summary
This is a Phase 1/2, open-label first-in-human study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLU-451 monotherapy and BLU-451 in combination with platinum-based chemotherapy (carboplatin and pemetrexed). All participants will receive BLU-451 on a 21-day treatment cycle.
Primary Outcome
MTD determination: Dose-limiting toxicities (DLTs) rate
Interventions
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG BLU-451
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2022-03-04 |
| Est. Completion | 2024-07-31 |
| Phase | Phase 1 |
Why NCT05241873 stopped before completion
NCT05241873 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% higher).
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT05241873 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05241873 about?
NCT05241873 is a clinical study titled "(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations". This is a Phase 1/2, open-label first-in-human study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLU-451 monotherapy and BLU-451 in combination with platinum-based chemotherapy (carboplatin and pemetrexed). All participants will receive BLU-451 on a 21-day trea...
What is the current status of trial NCT05241873?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2022-03-04. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT05241873?
The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), BLU-451 (DRUG).
Who is sponsoring clinical trial NCT05241873?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05241873's enrollment target sits among peer trials
103 541st of 2000 higher than 1,458 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI